Cargando…

Iontophoresis of Biological Macromolecular Drugs

Over the last few decades, biological macromolecular drugs (e.g., peptides, proteins, and nucleic acids) have become a significant therapeutic modality for the treatment of various diseases. These drugs are considered superior to small-molecule drugs because of their high specificity and favorable s...

Descripción completa

Detalles Bibliográficos
Autores principales: Hasan, Mahadi, Khatun, Anowara, Kogure, Kentaro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8953920/
https://www.ncbi.nlm.nih.gov/pubmed/35335900
http://dx.doi.org/10.3390/pharmaceutics14030525
_version_ 1784675967368691712
author Hasan, Mahadi
Khatun, Anowara
Kogure, Kentaro
author_facet Hasan, Mahadi
Khatun, Anowara
Kogure, Kentaro
author_sort Hasan, Mahadi
collection PubMed
description Over the last few decades, biological macromolecular drugs (e.g., peptides, proteins, and nucleic acids) have become a significant therapeutic modality for the treatment of various diseases. These drugs are considered superior to small-molecule drugs because of their high specificity and favorable safety profiles. However, such drugs are limited by their low oral bioavailability and short half-lives. Biological macromolecular drugs are typically administrated via invasive methods, e.g., intravenous or subcutaneous injections, which can be painful and induce needle phobia. Noninvasive transdermal delivery is an alternative administration route for the local and systemic delivery of biological macromolecular drugs. However, a challenge with the noninvasive transdermal delivery of biological macromolecular drugs is the outermost layer of the skin, known as the stratum corneum, which is a physical barrier that restricts the entry of extraneous macromolecules. Iontophoresis (IP) relies on the application of a low level of electricity for transdermal drug delivery, in order to facilitate the skin permeation of hydrophilic and charged molecules. The IP of several biological macromolecular drugs has recently been investigated. Herein, we review the IP-mediated noninvasive transdermal delivery of biological macromolecular drugs, their routes of skin permeation, their underlying mechanisms, and their advance applications.
format Online
Article
Text
id pubmed-8953920
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-89539202022-03-26 Iontophoresis of Biological Macromolecular Drugs Hasan, Mahadi Khatun, Anowara Kogure, Kentaro Pharmaceutics Review Over the last few decades, biological macromolecular drugs (e.g., peptides, proteins, and nucleic acids) have become a significant therapeutic modality for the treatment of various diseases. These drugs are considered superior to small-molecule drugs because of their high specificity and favorable safety profiles. However, such drugs are limited by their low oral bioavailability and short half-lives. Biological macromolecular drugs are typically administrated via invasive methods, e.g., intravenous or subcutaneous injections, which can be painful and induce needle phobia. Noninvasive transdermal delivery is an alternative administration route for the local and systemic delivery of biological macromolecular drugs. However, a challenge with the noninvasive transdermal delivery of biological macromolecular drugs is the outermost layer of the skin, known as the stratum corneum, which is a physical barrier that restricts the entry of extraneous macromolecules. Iontophoresis (IP) relies on the application of a low level of electricity for transdermal drug delivery, in order to facilitate the skin permeation of hydrophilic and charged molecules. The IP of several biological macromolecular drugs has recently been investigated. Herein, we review the IP-mediated noninvasive transdermal delivery of biological macromolecular drugs, their routes of skin permeation, their underlying mechanisms, and their advance applications. MDPI 2022-02-26 /pmc/articles/PMC8953920/ /pubmed/35335900 http://dx.doi.org/10.3390/pharmaceutics14030525 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Hasan, Mahadi
Khatun, Anowara
Kogure, Kentaro
Iontophoresis of Biological Macromolecular Drugs
title Iontophoresis of Biological Macromolecular Drugs
title_full Iontophoresis of Biological Macromolecular Drugs
title_fullStr Iontophoresis of Biological Macromolecular Drugs
title_full_unstemmed Iontophoresis of Biological Macromolecular Drugs
title_short Iontophoresis of Biological Macromolecular Drugs
title_sort iontophoresis of biological macromolecular drugs
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8953920/
https://www.ncbi.nlm.nih.gov/pubmed/35335900
http://dx.doi.org/10.3390/pharmaceutics14030525
work_keys_str_mv AT hasanmahadi iontophoresisofbiologicalmacromoleculardrugs
AT khatunanowara iontophoresisofbiologicalmacromoleculardrugs
AT kogurekentaro iontophoresisofbiologicalmacromoleculardrugs